ID   Huh-7
AC   CVCL_0336
SY   HuH-7; HUH-7; HuH7; Huh7; HUH7; HUH7.0; JTC-39; Japanese Tissue Culture-39
DR   BTO; BTO:0001950
DR   CLO; CLO_0050850
DR   CLO; CLO_0050853
DR   EFO; EFO_0005384
DR   MCCL; MCC:0000232
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471912
DR   BioSample; SAMN03472130
DR   BioSample; SAMN10987834
DR   CCLE; HUH7_LIVER
DR   CCLV; CCLV-RIE 1079
DR   CCRID; 3111C0001CCC000679
DR   CCRID; 3131C0001000700182
DR   CCRID; 3153C0001000000221
DR   CCTCC; GDC0134
DR   Cell_Model_Passport; SIDM00585
DR   CGH-DB; 453-3
DR   CGH-DB; 9072-4
DR   ChEMBL-Cells; CHEMBL3307515
DR   ChEMBL-Targets; CHEMBL614039
DR   CLS; 300156/p7178_HuH7
DR   Cosmic; 871515
DR   Cosmic; 873395
DR   Cosmic; 907071
DR   Cosmic; 945154
DR   Cosmic; 948063
DR   Cosmic; 979730
DR   Cosmic; 1187330
DR   Cosmic; 1351512
DR   Cosmic; 1518226
DR   Cosmic; 1622751
DR   Cosmic; 1995450
DR   Cosmic; 2023863
DR   Cosmic; 2162528
DR   Cosmic; 2321028
DR   Cosmic; 2668283
DR   Cosmic; 2674232
DR   Cosmic-CLP; 907071
DR   DepMap; ACH-000480
DR   ENCODE; ENCBS226AAA
DR   FCS-free; 213-2-437-1-3-3
DR   FCS-free; 213-2-540-1-3-3
DR   GDSC; 907071
DR   GEO; GSM207048
DR   GEO; GSM388882
DR   GEO; GSM388883
DR   GEO; GSM388884
DR   GEO; GSM481447
DR   GEO; GSM501781
DR   GEO; GSM565880
DR   GEO; GSM816641
DR   GEO; GSM827171
DR   GEO; GSM887149
DR   GEO; GSM888221
DR   GEO; GSM936763
DR   GEO; GSM1178257
DR   GEO; GSM1178258
DR   GEO; GSM1374566
DR   GEO; GSM1669919
DR   GEO; GSM2551570
DR   IARC_TP53; 2011
DR   JCRB; JCRB0403
DR   KCB; KCB 200970YJ
DR   KCLB; 60104
DR   LiGeA; CCLE_245
DR   LIMORE; HuH7
DR   LINCS_LDP; LCL-1926
DR   Lonza; 244
DR   PharmacoDB; HuH7_640_2019
DR   PRIDE; PXD001339
DR   PRIDE; PXD005955
DR   PRIDE; PXD008190
DR   RCB; RCB1366
DR   RCB; RCB1942
DR   TKG; TKG 0206
DR   TOKU-E; 3614
DR   Wikidata; Q27555640
RX   DOI=10.1007/978-4-431-68349-0_4;
RX   DOI=10.1101/2020.02.17.953281;
RX   DOI=10.11418/jtca1981.12.3_221;
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=6203805;
RX   PubMed=8389256;
RX   PubMed=8835345;
RX   PubMed=9290701;
RX   PubMed=9359923;
RX   PubMed=10523694;
RX   PubMed=12029633;
RX   PubMed=15708988;
RX   PubMed=15767549;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23285155;
RX   PubMed=23505090;
RX   PubMed=23887712;
RX   PubMed=24973239;
RX   PubMed=25485619;
RX   PubMed=25574106;
RX   PubMed=27329724;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29610054;
RX   PubMed=29774518;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31378681;
RX   PubMed=31395879;
RX   PubMed=31978347;
WW   https://en.wikipedia.org/wiki/Huh7
WW   http://huh7.com/
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/Huh-7_Crawford_protocol.pdf
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-309.html
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=1692
WW   http://www.cellresource.cn/fdetail.aspx?id=2172
WW   http://www.cellresource.cn/fdetail.aspx?id=2792
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Japanese.
CC   Doubling time: 32.2 hours (PubMed=31378681); ~48 hours (CLS).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for KDR p.Gln472His (c.1416A>T) (PubMed=29774518).
CC   Sequence variation: POLD3 p.Lys70Arg (c.209A>G) (DOI=10.1101/2020.02.17.953281).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (PubMed=31378681).
CC   Sequence variation: Homozygous for TP53 p.Tyr220Cys (c.659A>G) (ClinVar=VCV000127819) (PubMed=8389256; PubMed=29774518; PubMed=31395879).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.56%; Native American=0%; East Asian, North=79.68%; East Asian, South=13.08%; South Asian=0%; European, North=0%; European, South=5.69% (PubMed=30894373).
ST   Source(s): CCRID; CLS; Cosmic-CLP; JCRB; KCLB; PubMed=25877200; PubMed=29774518; PubMed=31378681; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D12S391: 20 (CLS)
ST   D12S391: 20,21 (CCRID)
ST   D13S317: 10 (CLS; RCB)
ST   D13S317: 10,11 (CCRID; Cosmic-CLP; JCRB; KCLB; PubMed=25877200; PubMed=29774518; PubMed=31378681; TKG)
ST   D16S539: 10
ST   D18S51: 15
ST   D19S433: 13,14
ST   D1S1656: 16
ST   D21S11: 30
ST   D2S1338: 19
ST   D3S1358: 15
ST   D5S818: 12
ST   D6S1043: 13,15
ST   D7S820: 11
ST   D8S1179: 14,15
ST   FGA: 22,23
ST   Penta D: 12
ST   Penta E: 11
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 16,18 (CCRID; Cosmic-CLP; JCRB; KCLB; PubMed=25877200; PubMed=29774518; PubMed=31378681; RCB; TKG)
ST   vWA: 18 (CLS)
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 34
//
RX   DOI=10.1007/978-4-431-68349-0_4;
RA   Alexander J.J.;
RT   "Human hepatoma cell lines.";
RL   (In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987).
//
RX   DOI=10.1101/2020.02.17.953281;
RA   Kawamoto M., Yamaji T., Saito K., Satomura K., Endo T., Fukasawa M.,
RA   Hanada K., Osada N.;
RT   "Identification of characteristic genomic markers in human hepatoma
RT   Huh7 and Huh7.5.1-8 cell lines.";
RL   bioRxiv 2020:953281-953281(2020).
//
RX   DOI=10.11418/jtca1981.12.3_221;
RA   Namba M., Nakabayashi H., Doi I., Sato J., Miyazaki M.;
RT   "Cellular characteristics and utilization of human hepatoma cell lines
RT   which were established in our laboratory and distributed by Japanese
RT   Cancer Research Resources Bank.";
RL   Tissue Cult. Res. Commun. 12:221-227(1993).
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   PubMed=6203805; DOI=10.20772/cancersci1959.75.2_151;
RA   Nakabayashi H., Taketa K., Yamane T., Miyazaki M., Miyano K., Sato J.;
RT   "Phenotypical stability of a human hepatoma cell line, HuH-7, in
RT   long-term culture with chemically defined medium.";
RL   Gann 75:151-158(1984).
//
RX   PubMed=8389256; DOI=10.1093/carcin/14.5.987;
RA   Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T.,
RA   Harris C.C.;
RT   "p53 gene mutation and integrated hepatitis B viral DNA sequences in
RT   human liver cancer cell lines.";
RL   Carcinogenesis 14:987-992(1993).
//
RX   PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A;
RA   Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K., Teruya K.,
RA   Kosaka T., Tsuji T., Namba M.;
RT   "Persistence of hepatitis C virus RNA in established human
RT   hepatocellular carcinoma cell lines.";
RL   J. Med. Virol. 48:133-140(1996).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-I., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
//
RX   PubMed=10523694; DOI=10.3892/or.6.6.1267;
RA   Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.;
RT   "Yeast functional assay of the p53 gene status in 11 cell lines and 26
RT   surgical specimens of human hepatocellular carcinoma.";
RL   Oncol. Rep. 6:1267-1271(1999).
//
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M.,
RA   Inazawa J.;
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
//
RX   PubMed=15708988; DOI=10.1128/JVI.79.5.2689-2699.2005;
RA   Sumpter R. Jr., Loo Y.-M., Foy E., Li K., Yoneyama M., Fujita T.,
RA   Lemon S.M., Gale M. Jr.;
RT   "Regulating intracellular antiviral defense and permissiveness to
RT   hepatitis C virus RNA replication through a cellular RNA helicase,
RT   RIG-I.";
RL   J. Virol. 79:2689-2699(2005).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23285155; DOI=10.1371/journal.pone.0052697;
RA   Murayama A., Sugiyama N., Yoshimura S., Ishihara-Sugano M., Masaki T.,
RA   Kim S., Wakita T., Mishiro S., Kato T.;
RT   "A subclone of HuH-7 with enhanced intracellular hepatitis C virus
RT   production and evasion of virus related-cell cycle arrest.";
RL   PLoS ONE 7:E52697-E52697(2012).
//
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y.,
RA   Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218-2218(2013).
//
RX   PubMed=24973239; DOI=10.1099/vir.0.065995-0;
RA   Richter M., Reimann I., Schirrmeier H., Kirkland P.D., Beer M.;
RT   "The viral envelope is not sufficient to transfer the unique broad
RT   cell tropism of Bungowannah virus to a related pestivirus.";
RL   J. Gen. Virol. 95:2216-2222(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25574106; DOI=10.3748/wjg.v21.i1.311;
RA   Cevik D., Yildiz G., Ozturk M.;
RT   "Common telomerase reverse transcriptase promoter mutations in
RT   hepatocellular carcinomas from different geographical locations.";
RL   World J. Gastroenterol. 21:311-317(2015).
//
RX   PubMed=27329724; DOI=10.18632/oncotarget.10161;
RA   Watari K., Nishitani A., Shibata T., Noda M., Kawahara A., Akiba J.,
RA   Murakami Y., Yano H., Kuwano M., Ono M.;
RT   "Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy
RT   of rapalogs for treating hepatocellular carcinoma.";
RL   Oncotarget 7:47403-47417(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003;
RA   Shi J., Wang X., Lyu L., Jiang H., Zhu H.-J.;
RT   "Comparison of protein expression between human livers and the hepatic
RT   cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics:
RT   Focusing on drug-metabolizing enzymes.";
RL   Drug Metab. Pharmacokinet. 33:133-140(2018).
//
RX   PubMed=29774518; DOI=10.1007/s13577-018-0212-3;
RA   Kasai F., Hirayama N., Ozawa M., Satoh M., Kohara A.;
RT   "HuH-7 reference genome profile: complex karyotype composed of massive
RT   loss of heterozygosity.";
RL   Hum. Cell 31:261-267(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574-3574(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//